Description
This is a ppt about Dr Reddy's Road to Success.
‘The day 11 April 2001 is etched in my mind. That was the morning the symbolic opening bell at New York Stock Exchange (NYSE) rang and your company became the first Asia Pacific pharmaceutical company outside of Japan and the sixth Indian company to be listed on the NYSE’.
- Dr. Anji Reddy's speech at the 17th Annual General Meeting.
Dr.Reddy?s
Life.Research.Hope
WHEN IT ALL BEGAN…
•
Dr. Reddy?s Laboratories founded in 1984 by Dr. K. Anji Reddy has become India?s biggest Pharmaceutical Company Began as a supplier to Indian drug manufacturers
•
•
Reddy?s manufactures and markets a wide range of pharmaceuticals in India and overseas
The company has more than 190 medications ready for patients to take, 60 active pharmaceutical ingredients, for drug manufacture, diagnostic kits, critical care and biotechnology products
•
BOARD OF DIRECTORS
• • • • • • • • •
•
Dr. K. Anji Reddy Mr. G.V Prasad Mr. Satish Reddy Mr. Anupam Puri Prof. Krishna G. Palepu Dr. Omkar Goswami Mr. P.N Devarajan Dr. P. Satyanarayana Rao Mr. Ravi Bhoothalingam Dr. V. Mohan
WHAT’S IN THE BUSINESS…
•
Dr. Reddy?s Laboratories is India?s third largest pharmaceutical company It?s business includes PSAI (Pharmaceutical Service and Active Ingredients), Global Generics and Innovation (Discovery Research, Biologics and Speciality Pharmaceuticals) The company?s products are marketed in over 100 countries with an emphasis in North America, Europe, Russia, India and emerging markets The company conducts NCE drug discovery research at its research facilities in Atlanta (USA) and Hyderabad (INDIA)
•
•
•
IT’S PRESENCE…
THE GROUND ROOTS…
• PLANT LOCATION
• There are various plants located in Andhra Pradesh, Pondicherry, Goa, Himachal Pradesh • There is a manufacturing unit in Mexico • A Research Facility at the UK
• HEAD OFFICE
• The headquarters of Dr. Reddy?s laboratories is located at Hyderabad, Andhra Pradesh • It has representative offices at various locations all over the globe
THE BACKBONE…
TURNOVER AND NET PROFIT
YEAR 2005 - 06 Net Revenue (in Rs. million) 24,267 Net Profit (in Rs. million) 1,629
2006 - 07
2007 - 08
65,095
50,006
9,327
4,678
ARRAY OF PRODUCTS
• Some of the Top Ten brands in India
• • • • • • • • • • Omize Nise Stamlo Stamlo Beta Enam Atocor Razo Recliment Clamp Mintop
THE SKY’S THE LIMIT…
Dr. Reddy „s Laboratory is responding to challenges and opportunities in the market through ambitious corporate strategies
•
Brand Formulation will show the greatest change in relative contribution to revenue from 2006-2012 Pursuing growth in the relatively untapped „biogenerics? market Dr. Reddy?s generic division will achieve strong growth from 2006-2012 Acquisition of Betapharm, an important milestone
•
• •
MORE INVESTMENT PLANS…
•
Dr. Reddy?s Laboratories is all set to invest nearly 4.5 billion ($100 million ) as part of their expansion drive in Andhra Pradesh, the company?s home state
In the year 2008, the company has sold 2 different biogenerics in India and has plans to add one drug per year in the next eight years The much anticipated drug from the Dr. Reddy?s staple is the Polypill - a first-of-its-kind tablet to tackle heart diseases. Research work are still in progress and the drug is expected to be available in the Indian markets by 2010.
•
•
SOME OF THE POTHOLES…
•
On July 01st 2000, the entire formulations unit of DRL at Bachupalli, Hyderabad came to a virtual stand still with employees going on an indefinite strike protesting against „arbitrary service conditions and unfair labor practices?
The strike was called off exactly after one month after the company officials managed to reach an agreement with the trade unions on the working hours of all the employees of the company.
•
SURVIVAL OF THE ‘FITTEST’…
•
Mylan Laboratories is the third largest generic producer in the US Barr Pharmaceutical (BPL) is a split generic/brand manufacturing
•
•
•
Sandoz, a generic version of Novartis AG (NVS)
Teva Pharmaceutical Industries (USA) is one of the largest producers of generic drugs In the Indian arena, it faces competition from companies such as Wockhardt, Cipla, Sun Pharm, GlaxoSmithKline Consumer HealthCare Ltd, East India Pharmaceutical Works Ltd., RPG Enterprise, Dabur India Ltd
•
WHY IT STANDS OUT…
•
Emerged as a trusted supplier of value added advanced intermediaries and APIs to generic as well as innovator companies Its one of the few integrated pharma companies to provide Custom Pharmaceutical Services Emerging as a “Partner of Choice” for innovator companies globally It has a “Low Cost” advantage in the global arena
•
•
•
KEY MILESTONES - 2008
•
Acquires BASF pharmaceuticals manufacturing contract and related facilities at Shreveport, Louisana Acquires Dow?s Pharma small molecule business at its Mirfield and Cambridge facility, UK
•
THANK YOU
REFERENCES…
•
http://www.bioportfolio.com/cgibin/acatalog/info_54.html
doc_205470300.ppt
This is a ppt about Dr Reddy's Road to Success.
‘The day 11 April 2001 is etched in my mind. That was the morning the symbolic opening bell at New York Stock Exchange (NYSE) rang and your company became the first Asia Pacific pharmaceutical company outside of Japan and the sixth Indian company to be listed on the NYSE’.
- Dr. Anji Reddy's speech at the 17th Annual General Meeting.
Dr.Reddy?s
Life.Research.Hope
WHEN IT ALL BEGAN…
•
Dr. Reddy?s Laboratories founded in 1984 by Dr. K. Anji Reddy has become India?s biggest Pharmaceutical Company Began as a supplier to Indian drug manufacturers
•
•
Reddy?s manufactures and markets a wide range of pharmaceuticals in India and overseas
The company has more than 190 medications ready for patients to take, 60 active pharmaceutical ingredients, for drug manufacture, diagnostic kits, critical care and biotechnology products
•
BOARD OF DIRECTORS
• • • • • • • • •
•
Dr. K. Anji Reddy Mr. G.V Prasad Mr. Satish Reddy Mr. Anupam Puri Prof. Krishna G. Palepu Dr. Omkar Goswami Mr. P.N Devarajan Dr. P. Satyanarayana Rao Mr. Ravi Bhoothalingam Dr. V. Mohan
WHAT’S IN THE BUSINESS…
•
Dr. Reddy?s Laboratories is India?s third largest pharmaceutical company It?s business includes PSAI (Pharmaceutical Service and Active Ingredients), Global Generics and Innovation (Discovery Research, Biologics and Speciality Pharmaceuticals) The company?s products are marketed in over 100 countries with an emphasis in North America, Europe, Russia, India and emerging markets The company conducts NCE drug discovery research at its research facilities in Atlanta (USA) and Hyderabad (INDIA)
•
•
•
IT’S PRESENCE…
THE GROUND ROOTS…
• PLANT LOCATION
• There are various plants located in Andhra Pradesh, Pondicherry, Goa, Himachal Pradesh • There is a manufacturing unit in Mexico • A Research Facility at the UK
• HEAD OFFICE
• The headquarters of Dr. Reddy?s laboratories is located at Hyderabad, Andhra Pradesh • It has representative offices at various locations all over the globe
THE BACKBONE…
TURNOVER AND NET PROFIT
YEAR 2005 - 06 Net Revenue (in Rs. million) 24,267 Net Profit (in Rs. million) 1,629
2006 - 07
2007 - 08
65,095
50,006
9,327
4,678
ARRAY OF PRODUCTS
• Some of the Top Ten brands in India
• • • • • • • • • • Omize Nise Stamlo Stamlo Beta Enam Atocor Razo Recliment Clamp Mintop
THE SKY’S THE LIMIT…
Dr. Reddy „s Laboratory is responding to challenges and opportunities in the market through ambitious corporate strategies
•
Brand Formulation will show the greatest change in relative contribution to revenue from 2006-2012 Pursuing growth in the relatively untapped „biogenerics? market Dr. Reddy?s generic division will achieve strong growth from 2006-2012 Acquisition of Betapharm, an important milestone
•
• •
MORE INVESTMENT PLANS…
•
Dr. Reddy?s Laboratories is all set to invest nearly 4.5 billion ($100 million ) as part of their expansion drive in Andhra Pradesh, the company?s home state
In the year 2008, the company has sold 2 different biogenerics in India and has plans to add one drug per year in the next eight years The much anticipated drug from the Dr. Reddy?s staple is the Polypill - a first-of-its-kind tablet to tackle heart diseases. Research work are still in progress and the drug is expected to be available in the Indian markets by 2010.
•
•
SOME OF THE POTHOLES…
•
On July 01st 2000, the entire formulations unit of DRL at Bachupalli, Hyderabad came to a virtual stand still with employees going on an indefinite strike protesting against „arbitrary service conditions and unfair labor practices?
The strike was called off exactly after one month after the company officials managed to reach an agreement with the trade unions on the working hours of all the employees of the company.
•
SURVIVAL OF THE ‘FITTEST’…
•
Mylan Laboratories is the third largest generic producer in the US Barr Pharmaceutical (BPL) is a split generic/brand manufacturing
•
•
•
Sandoz, a generic version of Novartis AG (NVS)
Teva Pharmaceutical Industries (USA) is one of the largest producers of generic drugs In the Indian arena, it faces competition from companies such as Wockhardt, Cipla, Sun Pharm, GlaxoSmithKline Consumer HealthCare Ltd, East India Pharmaceutical Works Ltd., RPG Enterprise, Dabur India Ltd
•
WHY IT STANDS OUT…
•
Emerged as a trusted supplier of value added advanced intermediaries and APIs to generic as well as innovator companies Its one of the few integrated pharma companies to provide Custom Pharmaceutical Services Emerging as a “Partner of Choice” for innovator companies globally It has a “Low Cost” advantage in the global arena
•
•
•
KEY MILESTONES - 2008
•
Acquires BASF pharmaceuticals manufacturing contract and related facilities at Shreveport, Louisana Acquires Dow?s Pharma small molecule business at its Mirfield and Cambridge facility, UK
•
THANK YOU
REFERENCES…
•
http://www.bioportfolio.com/cgibin/acatalog/info_54.html
doc_205470300.ppt